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Abstract 
 
 
 
Background: 
 
Migraine  causes  crippling  attacks  of  severe  head  pain  along  with  associated  nausea, 
 
vomiting, photophobia and/or phonophobia. The aim of this study was to investigate single 
 
nucleotide polymorphisms (SNPs) in the adenosine deaminase, RNA-specific, B1 (ADARB1) 
 
and adenosine deaminase, RNA specific, B2 (ADARB2) genes in an Australian case-control 
Caucasian population for association with migraine. Both candidate genes are highly 
expressed in the central nervous system (CNS) and fit criteria for migraine neuropathology. 
SNPs in the ADARB2 gene were previously found to be positively associated with migraine 
in a pedigree-based GWAS using the genetic isolate of Norfolk Island, Australia. The 
ADARB1 gene was also chosen for investigation due to its important function in editing 
neurotransmitter receptor transcripts. 
Methods: 
 
Four SNPs in ADARB1 and nine in ADARB2 were selected by inspecting blocks of LD in 
Haploview for genotyping using either TaqMan or Sequenom assays. These SNPs were 
genotyped in two-hundred and ninety one patients who satisfied the International 
Classification of Headache Disorders, ICHD-II 2004 diagnostic criteria for migraine and 
three-hundred and fourteen controls and PLINK was used for association testing. 
Results: 
 
Chi-square (χ2) analysis found no significant association between any of the SNPs tested in 
the ADARB1 and ADARB2 genes in this study and the occurrence of migraine. 
Conclusions: 
 
In contrast to findings that SNPs in the ADARB2 gene were positively associated with 
migraine in the Norfolk Island population, we find no evidence to support the involvement of 
RNA editing genes in migraine susceptibility in an Australian Caucasian population. 
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Background 
 
The International Headache Society (IHS) defines migraine as a recurrent headache disorder 
typified by painful attacks lasting 4-72 hours [1].  Classification criteria recognize two types 
of migraine, migraine with aura (MA) and migraine without aura (MO) with the former 
accompanied by visual or auditory disturbances [1].  Migraine generally affects 12% of the 
Caucasian population showing up more often in females, a statistic correlated with instability 
of ovarian hormones [2]. Migraine has a major impact on the wellbeing and quality of life of 
sufferers and their families in part due to days missed from the workplace and higher direct 
health-care costs [3]. Numerous theories and models regarding migraine mechanisms have 
emerged; the most accepted opinion is that a combination of both vascular and neural events 
is involved in the initiation and perpetuation of a migraine attack [4,5]. Primarily the 
generation of pain is attributed to complex processes within the nervous system that activate 
the trigeminovascular system consisting of the trigeminal nerve and its ramifications which 
regulate cerebral blood flow and the release of inflammatory molecules. The fact that the 
diameter of cranial blood vessels along with other functions is controlled by signals 
transmitted by nerves is further evidence to support a neurogenic theory. The aura on the 
other hand, occurs in only a minority of migraineurs and has been attributed to an 
electrophysiological phenomenon, first reported in epilepsy, termed Cortical Spreading 
Depression (CSD) [6]. 
 
 
 
Interactions between the environment and the genotype are important in shaping the migraine 
phenotype. Population based twin studies have confirmed a genetic influence ranging from 
0.34 to 0.57 [7]. Genetic studies of a rare, and more severe migraine subtype, Familial 
Hemiplegic Migraine (FHM), have identified mutations in three causal genes that code for 
ion channels involved in neuronal signalling and have provided hypotheses applicable to 
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common migraine [8]. Functional studies in cellular and animal models of mutant alleles 
provide direct evidence for neuronal hyperexcitability as one cellular mechanism underlying 
headache or aura in FHM [9]. For the most part, genes causing more common types of 
 
migraine have been identified from neurological, vascular and hormonal pathways and in 
 
2010 the first functional variant to show linkage to familial MA was identified in TRESK, a 
potassium channel involved in neuronal excitability [10]. While genome wide association 
studies  (GWAS)  have  shed  new  light  on  the  types  of  genes  involved  in  migraine 
 
susceptibility, many candidate gene association studies have focused on neurotransmitter- 
related pathways, as these pathways are considered to play a significant role in the migraine 
process. Therefore genes affecting synthesis and  activity of  neurotransmitters, including 
RNA editing genes, are potential candidates for involvement in migraine susceptibility. 
 
 
 
Isolated founder populations offer several advantages over mainstream (outbred) populations 
for genomic studies of disease, as both environmental noise and genetic heterogeneity is 
reduced. We have used the population of Norfolk Island, an island off the east coast of 
Australia, for genetic studies on migraine as it has well-documented family histories and an 
increased prevalence of the disorder [11]. We previously identified four SNPs forming a 
22kb haplotype block in ADARB2 (Table 1 and Figure 1) that were positively associated with 
migraine susceptibility in a pedigree-based GWAS (pGWAS) of the population of Norfolk 
Island. [11]. ADARB2 is a member of the double-stranded RNA adenosine deaminase family 
of RNA-editing enzymes [12]. The enzymatic activity of ADARs leads to the chemical 
modification of Adenosine-to-Inosine (A-to-I) in specific coding regions which are then 
translated as guanosines by the cells translational machinery [13]. A-to-I RNA editing is a 
post-transcriptional process that permanently alters the nucleotide sequence of an RNA 
molecule resulting in the synthesis of proteins not encoded by the original gene sequence 
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[14].  This is a form of chemical recoding that changes specific amino acid residues and alters 
the biological function of translated molecules, which is most clearly demonstrated by an 
alteration  in  channel  properties  including  the  Ca
2+   
permeability  of  glutamate  receptors 
(GluRs) [15]. Perturbed A-to-I RNA editing has been implicated in human cancer and viral 
infections and neurodegenerative/neurological diseases such as dyschromatosis symmetrica 
hereditaria (DSH), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and 
Huntington’s disease epilepsy, depression and  schizophrenia [16,17].  In  ALS  inefficient 
RNA editing fails to substitute an arginine for a glutamine residue in the GluR2 Q/R site of 
glutamate AMPA receptors in the spinal motor neurons and is proposed as a mechanism 
responsible for motor neuron death [18]. 
 
 
 
 
ADARB2 (also known as ADAR3) comprises 10 exons spanning a genomic region of 9.5kb on 
chromosome 10p15.3 and encodes a catalytically inactive protein, expressed in brain, 
amygdala and thalamus [12]. One SNP rs2271275 confers a (Thr-Ala) amino acid change in 
the protein structure and has previously been associated with early-onset obsessive- 
compulsive disorder in some American families in a genome-wide linkage scan [19]. In 
addition to ADARB2 SNPs, the Norfolk Island pGWAS also found two SNPs in the glutamate 
receptor, metabotropic 7 (GRM7) gene and one SNP in the 5-hydroxytryptamine serotonin 
receptor 7 adenylate cyclase-coupled (HTR7) gene to be associated with migraine [11]. 
Collectively, association of variants in these neurotransmitter-related genes ADARB2; GRM7; 
HTR7 connected by a common neurological pathway supports current theories of a perturbed 
serotonin and glutamate mechanism in migraine and in the Norfolk pedigree. 
Previous studies have reported positive associations of SNPs in various neurotransmitter- 
related genes, e.g. DBH [20] and SLC6A3 [21], with migraine in a number of case-control 
populations. 
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Considering the association of ADARB2 with migraine in the Norfolk Island pGWAS we 
decided to investigate SNPs in this gene, as well as another RNA editing gene, ADARB1, in 
an Australian migraine case-control population.  ADARB1 encodes an RNA editing enzyme, 
expressed mainly in the CNS, that is involved in the downstream regulation of 
neurotransmitters [22]. The gene is of potential interest with respect to migraine susceptibility 
as the glutamate and serotonin receptor gene RNAs are the predominant substrates modified 
by ADARB1 adenosine deamination [22].  ADARB1 (also known as ADAR2) spans a genomic 
region of 25 kb on chromosome 21q22.3 and comprises 16 exons and regulates its own 
expression through self-editing [23]. In this study we genotyped four SNPs in ADARB1 and 
nine SNPs in ADARB2 using either TaqMan or Sequenom assays to investigate their 
involvement in migraine. 
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Methods 
 
 
 
 
Case-control population 
The study was approved by the Griffith University Ethics Committee for experimentation in 
humans.  The  study  population  was  composed  of  291  cases  and  314  controls  and 
 
demographical  characteristics  of  the  population  are  reported  in  (Table  2).     Affected 
individuals were diagnosed as having MA or MO by an experienced clinical neurologist 
based on responses provided in a validated medical questionnaire in accordance with criteria 
determined by the International Headache Society (IHS) [1]. The migraine population 
consisted of  individuals of  Caucasian origin, recruited from the South East Queensland 
Region of Australia. The control population samples were obtained via the Genomics 
Research Centre Clinic, Southport and had no  history of  personal or  familial migraine. 
Signed informed consent was obtained from all patients before participation in the study. 
 
 
 
SNP selection 
 
HapMap CEU (Utah residents with Northern and Western European ancestry) SNP genotype 
data  was  downloaded for  each  candidate gene  and  a  total  of  8  haplotype blocks  were 
identified in the ADARB1 gene and 56 haplotype blocks in the ADARB2 gene in the program 
Haploview v4.2 [24]. Thirteen SNPs were selected in the ADARB1 and ADARB2 genes are 
spread out across the entire length of the gene and are located in different LD blocks and 
were mostly located in intronic regions of each gene (Table 3 and 4). 
 
 
 
 
Genotyping Methods 
 
Genomic DNA was extracted from peripheral blood samples using a salting out method as 
described by Miller et al., 1988 [25].  DNA was quantified and normalised to a concentration 
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of 20ng/µL for genotyping experiments. Nine SNPs were genotyped as part of a Sequenom 
 
plex, which allows high throughput multiplexing of the assays into a single well. Not all 
 
SNPs are compatible with the restraints required for primer design for this method, or can be 
 
run together so therefore we also used TaqMan assays to genotype five of the SNPs. For each 
 
SNP,  Sanger  sequencing  of  a  subset  of  samples  was  performed  on  a  ABI3500  (Life 
 
Technologies, Carlsband, CA, USA) to confirm the genotypes. 
 
 
 
 
 
Genotyping by TaqMan 
 
 
SNPs rs2838771, rs1051367 in ADARB1 and SNPs rs2271275, rs10903467, rs11250642 in 
ADARB2  were   genotyped  using   TaqMan®   SNP   Genotyping  Assays   from   Applied 
Biosystems (Life Technologies, Carlsband, CA, USA). Detailed information regarding SNPs 
genotyped in the ADARB1 and ADARB2 genes and a summary of assay conditions for each 
SNP are listed in Table 3. The genotyping protocol for each marker was exactly the same 
except for the use of the specific Primer-Probe Mix. The final optimized PCR reaction 
conditions consisted of 20ng of genomic DNA template, TaqMan Universal PCR Master Mix 
(1X), SNP genotyping assay probe-primer mix (20X), DNase-free water in a 5 µL reaction 
volume. The PCR thermocycling conditions consisted of one cycle at 95°C for 10 min, 
followed by 40 cycles at 95 °C for 15 s, 60°C for 1 min. The data were acquired during the 
annealing step and analysed using the 7900 system Sequence Detection System software 
Applied Biosystems (Life Technologies Corporation) in a 384-well plate format. Nuclease- 
free water was used as a negative control and DNA for each genotype included as positive 
controls. 
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Genotyping by Sequenom 
 
 
SNPs in the ADARB1 and ADARB2 genes were genotyped using the Sequenom MassARRAY 
system 4 platform, and Typer 4.0 software was used to carry out all genotyping work 
(MALDI-TOF; MassARRAY system, Sequenom Inc., San Diego, CA, USA). The primers 
for  PCR  and  iPLEX  reactions  were  designed  using  the  online  Assay  design  suite  1.0 
Sequenom software (available at: www.mysequenom.com/tools) and obtained from IDT (see 
Table  4)  (Integrated  DNA  Technologies,  Carolville,  Iowa,  USA).  PCR  and  extension 
reactions were performed in a 96-well plate according to the manufacturer’s instructions, 
using Sequenom reagents. Completed genotyping reactions were spotted in nanoliter volumes 
onto a matrix arrayed silicon chip with 96 elements (Sequenom SpectroCHIP) using the 
MassARRAY Nanodispenser. Spectro CHIPs were analyzed using the Bruker Autoflex 
MALDI-TOF mass spectrometer and the spectra were processed using the SpectroTYPER 
software (Sequenom) to yield genotypes. 
 
 
 
Statistical Analysis 
 
Hardy-Weinberg Equilibrium (HWE) was calculated for each SNP in case and control groups 
to detect deviation from the normal genotype distribution in the population. Chi-square (χ2) 
analysis was performed on SNPs in HWE to determine if significant differences existed in the 
genotype and allele frequencies in the migraine population versus controls. This analysis was 
 
completed in the software PLINK v1.07 [26].   Power estimates indicated that if the SNPs 
 
were to confer at least a two-fold increase in relative risk of migraine, the case and control 
 
groups used in this study are of sufficient size to have approximately 80% power to detect an 
 
association as statistically significant at the 0.05 level. 
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Results 
The  aim  of  this  study  was  to  determine if  SNPs  in  the  ADARB1  and  ADARB2  genes 
contribute to migraine susceptibility in an Australian case-control cohort. In this study, the 
following 4 SNPs in the ADARB1 gene: rs2838771, rs407133, rs422720, rs1051367, and the 
following 8 SNPs in the ADARB2 gene: rs3793733, rs7070629, rs10903467, rs10903479, 
rs11250642, rs7094094, rs10903520, rs884861 were in HWE and analysed for association. 
 
Genotypic and allelic distributions for all 12 SNPs genotyped are shown in Table 5. Minor 
 
Allele Frequencies obtained in this study were consistent with expected allele frequencies in 
 
HapMap–Utah residents with Northern and Western European ancestry (CEU) populations. 
 
Chi-square (χ2) analysis was performed for migraine cases versus controls. As Table 5 shows, 
 
for the majority of SNPs genotype and allele frequencies do not differ significantly between 
 
migraineurs and controls. An allelic p-value of 0.05 was observed for rs884861. However, 
 
the result for rs884861 is not significant with Bonferroni correction for multiple testing which 
 
gives  a  corrected  p-value  threshold  of  0.0042.  Thus  overall  there  was  no  significant 
 
association between migraine and the ADARB1 and ADARB2 SNPs investigated. 
 
 
 
 
 
Discussion 
 
Susceptibility to migraine is conferred by exposure to intrinsic and environmental triggering 
factors and genetics. Pinpointing SNPs associated with disease is one of the goals of GWAS 
and one of many approaches used to dissect the genetic basis of migraine. This study was 
undertaken to follow up findings from a pGWAS we previously conducted in the Norfolk 
Island pedigree which implicated four SNPs in the RNA editing gene ADARB2 in migraine, 
based on statistical significance [11]. These four SNPs, and others, in the RNA editing genes 
ADARB1 and ADARB2, were further investigated in an Australian migraine case-control 
population because they fit criteria for migraine neuropathology, i.e. a) are expressed in the 
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brain or CNS, b) regulate neurological pathways (e.g. neurotransmitters) and c) are plausibly 
related to migraine neuropathology (e.g. cellular hyperexcitability, ion channel disruption). 
Furthermore, retyping top-ranking SNPs from GWAS data in independent case-controls 
cohorts is important to determine the validity of GWAS findings and ascertain risk within 
different population groups. 
 
 
 
To date only a few association studies have investigated SNPs in the RNA editing genes 
ADARB1 and ADARB2 and none have been studied in migraine previously. Interestingly, a 
GWAS of US centenarians supports a role for RNA editors as important regulators of aging 
in humans. SNPs in ADARB2 were found to be associated with longevity and these findings 
were replicated in three independent cohorts of different genetic backgrounds [27]. Amore et 
al., 2004 identified a common neutral SNP in three out of seven patients with bipolar disorder 
in the ADARB1 gene but no major alteration [28]. In a separate study by Kostyrko et al., 2006 
analysed the coding sequence of ADARB1 and its association with bipolar affective disorder 
and did not find any mutations except one already known transition [29]. Oguro et al., 2012 
identified a longevity-associated SNP in ADARB2 rs2805533, which may modulate human 
longevity by regulating metabolic factors such as abdominal obesity and lipid profiles [30]. 
 
 
 
RNA editing is a physiologically important and conserved process necessary for proper 
development  and  functioning  of  neuronal  cells.  The  importance  of  this  process  is 
demonstrated   by   mice   deficient   in   the   RNA-editing   enzyme   ADARB1   which   die 
approximately 20 days post-birth and show early onset epilepsy [31]. This phenotype results 
from under editing of a critical position that determines calcium permeability in glutamate 
receptors of excitatory neurons [31]. ADARB1 plays an important role in ensuring 
neurotransmitter  receptor  transcripts  are  properly  edited  at  respective  points  [14].  The 
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particular editing function of ADARB1 upon the AMPA glutamate receptor subunit (GRIA2) 
pre-mRNA makes the investigation of ADARB1 in migraine interesting, because glutamate is 
a major mediator in the central nervous system and its regulation has been studied as a 
possible mechanism causing migraine. 
 
 
 
Although ADARB2 is catalytically inactive it has been shown in vitro that it can act as a 
competitor  of ADAR  (also  known  as  ADAR1) and ADARB1 by  binding  to  the  same 
transcripts and thus ADARB2 can decrease the efficiency of other RNA editing enzymes by 
preventing them from deaminating their substrate RNAs in regions of the brain where they 
are  co-expressed  [32]. ADARB2 may  therefore  be  reducing  the  total  number  of  edited 
transcripts via a competitive mechanism, which in turn may lead to poor ionic conductance 
and synaptic dysfunction in the CNS. One example that supports this hypothesis is perturbed 
A-to-I editing of the mRNA encoding the GRIA2 subunit of glutamate AMPA receptors 
which manifests in the disease amyotrophic lateral sclerosis (ALS) [33].  Functional studies 
are needed to further investigate the activity of ADARB2 in vivo. 
 
In this study we tested four SNPs in the ADARB1 gene and eight SNPs in the ADARB2 for 
association with migraine susceptibility. Results of χ2 analysis indicated that neither genotype 
 
nor allele frequency distributions for the migraine and control groups were significantly 
 
different  after  Bonferroni  correction  for  multiple  testing.  Although  we  were  unable  to 
replicate our findings from the Norfolk Island population implicating four ADARB2 SNPs in 
in migraine in an Australian Caucasian population, it does not exclude a role for ADARB2 in 
migraine in the unique Norfolk Island population isolate. This may be because rare variants 
that are over-represented in the unique pedigree structure of the Norfolk Island population 
contibuted to the initial finding and that the common variants selected for this study are not 
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relevent in the case-control population analysed here. Fine-mapping and sequencing for rare 
variants in the Norfolk Island samples could shed further light on this. 
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Conclusion 
 
 
In this study we found no evidence for SNPs in the RNA editing genes ADARB1 and 
ADARB2 to be associated with increased risk of migraine in an Australian Caucasian 
population. This result is in contrast to a pGWAS study of Norfolk Island which implicated a 
22 kb haploblock region in ADARB2 in migraine. Genetically isolated populations may carry 
unique genetic characteristics that are not always replicated in case-control cohorts. 
Nevertheless, both types of populations are useful to study the genetic structure underlying 
disease, providing direction to the investigation of susceptibility genes and genetic pathways. 
Considering that common migraine is caused by interactions of multiple loci, identifying and 
validating genetic factors that influence the disorder remains an important undertaking that 
may lead to improved strategies for management and treatment. 
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Figure 1 Haplotype block of 4 SNPs implicated in the ADARB2 gene in the 
 
Norfolk Island pGWAS [11]. 
  
 
 
Table 1 SNPs in ADARB2 associated with migraine in the Norfolk Island pGWAS adapted from [11]. 
 
 
 
 
 
Locus Gene No. SNPs in Gene NCBI dbSNP Ref No. NCBI build 37.1 position (BP) Function Minor/Major allele MAF Beta P Value 
10p15 ADARB2 4 rs10903399 1227868 Downstream C/T 0.330 0.64 7.68E−05 
   rs1046914 1228206 3Prime utr G/A 0.328 0.67 3.43E−05 
   rs2271275 1230968 Non-synon G/A 0.368 0.65 2.67E−05 
   rs883248 1250184 Intronic G/A 0.439 0.67 3.83E−06 
  
 
Table 2  Demographical characteristics of Migraine Cases and Controls. 
 
Parameter  Cases (n = 291) Controls (n = 314) 
 
Age: Mean (range)  
46.4 (-18-67) 
44.4 (18-63) 
 
Sex 
 
Male 70 89 
 
Female 221 225 
 
MA 227 N/A 
 
MO 64 N/A 
 
 
 
 
MA - migraine with aura, MO - migraine without aura, N/A - not applicable. 
  
 
 
Table 3 TaqMan Assay and SNP information. 
 
 
 
 
 
TaqMan Assay ID Gene SNP ID Position SNP Type Allele Change 
a
CEU MAF 
C__15831699_10 ADARB1 rs2838771 Chr.21: 46501576 Transversion Substitution C:G G=0.41 
C_1211569_1_ ADARB1 rs1051367 Chr.21: 46641968 Silent Mutation A:G G=0.47 
C_15959830_10 ADARB2 rs2271275 Chr.10: 1230968 Missense Mutation C:T C=0.34 
C_32118695_20 ADARB2 rs10903467 Chr.10: 1535739 Intron, Transition 
Substitution 
C:T T=0.44 
C__30856132_20 ADARB2 rs11250642 Chr.10: 1622644 Intron, Transition 
Substitution 
C:T T=0.50 
 
a
CEU MAF = HapMap Caucasian Minor Allele Frequency 
  
 
 
Table 4 SNPs genotyped in ADARB1 and ADARB2 by Sequenom. 
 
 
 
 
Gene SNP ID Forward, Reverse and Extension Primer Sequences Position SNP type Allele Change 
a
CEU MAF 
ADARB1 rs407133 F:  5’ ACGTTGGATGCCTGCTCTGCAGTAATGAAC 3’ 
R:  5’ ACGTTGGATGTCCTCCTCTCTTAACTCACG 3’ 
E:  5’ TCGGACCAATGCTGA 3’ 
45396317 Intron C:G G 0.46 
rs422720 F:  5’ ACGTTGGATGGGAAGCAGTACATGTTCATTG 3’ 
R:  5’ ACGTTGGATGGACTAATGCAGATGATCACC 3’ 
E:  5’ gggtCAGTACATGTTCATTGTAAGAATT 3’ 
45403382 Intron A:C C 0.36 
ADARB2 rs3793733 F:  5’ ACGTTGGATGCAACTCCATGTCAAAAGTGC 3’ 
R:  5’ ACGTTGGATGATGCCAGGACTCAGGTGCTT 3’ 
E:  5’caggAAGCATATTGTCAACCTTCCTC 3’ 
1411326 Missense G:A A 0.01 
rs7070629 F:  5’ ACGTTGGATGGATGAAAAAAGGATGCCATAC 3’ 
R:  5’ ACGTTGGATGCCTGTGATGCAGCTTCTCCT 3’ 
E:  5’ accttTGATGCAGCTTCTCCTGGCACA 3’ 
1414938 Intron G:A A 0.37 
rs10903479 F:  5’ ACGTTGGATGAGAACGCAATGCACTCTTCC 3’ 1581881 Intron A:T T 0.40 
  
 
 
 
  R:  5’ ACGTTGGATGTCGGTTTTGGAGTCTAGAGG 3’ 
E:  5’ CCTCATTGTCACAGAGT 3’ 
    
rs7094094 F:  5’ ACGTTGGATGTCTAGAAAATGCAGAAGGG 3’ 
R:  5’ ACGTTGGATGCTTGGGCTATACTTTTTGTG 3’ 
E:  5’CATTCAGTTGTTCTAATATTATATTGA 3’ 
1652840 Intron T:G G 0.38 
rs10903520 F:  5’ ACGTTGGATGTTACTCCTTAAGTGGAAGGG 3’ 
R:  5’ ACGTTGGATGACCATGATATCTACCCCTCC 3’ 
E:  5’ AAAGAAGCAGGCGTT 3’ 
1672481 Intron G:A A 0.39 
rs884861 F:  5’ ACGTTGGATGGAAAAACAGATAGACAAAGC 3’ 
R:  5’ ACGTTGGATGCCCTGGAATAACTTCAGGGT 3’ 
E:  5’ ACAGATAGACAAAGCAGAATATAT 3’ 
1765662 Intron C:G C 0.43 
 
 
 
a
CEU MAF = HapMap Caucasian Minor Allele Frequency 
 Table 5  Genotypic and allelic frequencies of migraine cases and controls and p- 
 
values derived from χ 2   analysis for SNPs investigated in the ADARB1 and 
 
ADARB2 genes. 
 
 
SNP Group Genotypes  Total Genoty  
a
MAF
 Allelic Hap-Map 
  a  
 
(n=) pic p- 
value 
p-value CEU MAF 
 
 
ADARB1 CC GC GG 
 
rs2838771  Cases 0.429 0.441 0.130 261 0.86 0.35 0.65 
 
Controls  0.405 0.461 0.134 247 0.36 G allele, 0.36 
 
GG GA AA 
 
rs407133  
Cases 0.178 0.519 0.303 264 
0.95 0.44 0.35 
 
Controls  0.179 0.529 0.292 291 0.44 G allele, 0.44 
 
CC CA AA 
 
 
rs422720  Cases 0.157 0.498 0.345 255 
0.64 0.42 0.35 
 
Controls  0.138 0.480 0.382 275 0.38 C allele, 0.38 
 
AA AG GG 
 
 
rs1051367  Cases 0.277 0.530 0.193 274 
0.53 0.46 0.40 
 
Controls  0.320 0.493 0.187 300 0.43 G allele, 0.43 
 
ADARB2 AA  
GA GG 
 
 
rs3793733 
Cases  
0.0 0.017 0.983 239 
b
0.32 0.008 0.32 
 
 
Controls  0.0 0.031 
0.969  
228 0.015 A allele, 0.00  
 
GG 
AA GA 
 
 
rs7070629 
Cases  
0.138 0.466 0.395 253 0.70 0.37 0.41 
 
 
Controls  0.125 0.444 0.430 279 0.35 A allele, 0.37 
  
  
TT 
 
CT 
 
CC 
 
 
rs10903467 
 
Cases 
 
0.183 
 
0.470 
 
0.347 
 
251 
 
0.16 
 
0.42 
 
0.11 
 
  
Controls 
0.205  
0.524 
 
0.271 
 
288 
  
0.47 
  
T allele, 0.48 
   
TT 
 
TA 
 
AA 
     
 
rs10903479 
 
Cases 
 
0.195 
 
0.489 
 
0.316 
 
266 
 
0.33 
 
0.44 
 
0.15 
 
  
Controls 
 
0.153 
 
0.490 
 
0.357 
 
294 
  
0.40 
  
T allele, 0.40 
   
TT 
 
CT 
 
CC 
     
 
rs11250642 
 
Cases 
 
0.200 
 
0.459 
 
0.341 
 
255 
 
0.34 
 
0.42 
 
0.31 
 
  
Controls 
 
0.200 
0.500  
0.300 
 
270 
  
0.45 
  
T allele, 0.45 
   
GG 
 
GT 
 
TT 
     
 
rs7094094 
 
Cases 
0.100  
0.420 
 
0.480 
 
246 
 
0.83 
 
0.37 
 
0.62 
 
  
Controls 
 
0.104 
 
0.442 
 
0.454 
 
269 
  
0.33 
  
G allele, 0.37 
   
AA 
 
GA 
 
GG 
     
rs10903520  
Cases 
 
0.114 
 
0.493 
 
0.393 
 
280 
 
0.55 
 
0.36 
 
0.62 
 
  
Controls 
 
0.144 
 
0.476 
 
0.380 
 
290 
  
0.38 
  
A allele, 0.38 
   
GG 
 
GC 
 
CC 
     
rs884861  
Cases 
 
0.161 
 
0.435 
 
0.404 
 
248 
 
0.16 
 
0.38 
 
0.05 
 
  
Controls 
 
0.220 
 
0.440 
 
0.340 
 
273 
  
0.44 
 G allele, 0.43 
 
 
a
MAF= Minor allele frequency 
 b
Heterozygous GA genotype versus homozygous AA genotype only as no homozygous GG 
 
individuals were detected. 
